Email this article Hypermethylation of the microRNA miR-124, miR-125b, miR-127, and miR-129 in ovarian carcinoma is involved in suppression of their expression and associated with both the development and progression of ovarian cancer
- Authors: Braga E.A.1,2, Pronina I.V.1, Utkin D.O.3, Filippova E.A.1, Burdennyy A.M.1, Loginov V.I.4, Fridman M.V.5, Kazubskaya T.P.6, Kushlinskii N.E.6
-
Affiliations:
- Institute of General Pathology and Pathophysiology
- Medical Genetic Science Center
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry
- Institute of General Pathology and Pathophysiology Medical Genetic Science Center
- Vavilov Institute of General Genetics
- N.N. Blokhin National Medical Research Centre of Oncology
- Issue: Vol 47, No 1 (2019)
- Pages: 47-53
- Section: ARTICLES
- URL: https://almclinmed.ru/jour/article/view/962
- DOI: https://doi.org/10.18786/2072-0505-2019-47-003
- ID: 962
Cite item
Full Text
Abstract
Rationale: We have previously identified a group of microRNA genes (MIR-107, MIR-1258, MIR-130b, MIR-34b/c, MIR-9-1, MIR-9-3 et al.), whose methylation was involved into the development and progression of ovarian cancer. Aim: To expand the range of microRNA genes hypermethylated in ovarian cancer and to study the role of this modification in the pathogenesis and progression of ovarian cancer. Materials and methods: The study was performed on a series of 76 ovarian cancer and 13 peritoneal metastases samples. The method of bisulfite DNA conversion followed by methylation-specific polymerase chain reaction (PCR) was used to assess the methylation status of the microRNA genes; the expression of these genes was measured by quantitative real-time PCR. Results: Compared to histologically unchanged ovarian tissue, there was a significant increase in methylation frequencies in the tumor samples for 6 microRNA genes studied: MIR-124-1, MIR-124-2, MIR-124-3, MIR-125B-1, MIR-127, and MIR-129-2 (p ≤ 10-3). The expression level of 4 microRNAs (miR-124-3p, miR-125b-5p, miR-127-5p, miR-129-5p) encoded by these genes was suppressed, with a significant correlation between changes in their expression levels and the gene methylation (rs = 0.63–0.94, p ≤ 10-4). In addition, there were statistically significant associations between methylation of 5 genes (MIR-124-2, MIR-124-3, MIR-125B-1, MIR-127, and MIR-129-2) and the parameters of cancer progression, such as its clinical stage, metastatic spread, tumor size and invasion, and to a lesser extent with a decrease in the differentiation grade. The association of 5 microRNA genes with metastatic spread was confirmed by the analysis of peritoneal macro-metastases from 13 patients. Conclusion: We have demonstrated the functional significance of aberrant methylation in a group of microRNA genes for suppression of their expression in ovarian carcinomas. There is an association of microRNA gene hypermethylation with the progression of ovarian cancer, including metastatic spread to the peritoneum.
About the authors
E. A. Braga
Institute of General Pathology and Pathophysiology;Medical Genetic Science Center
Author for correspondence.
Email: eleonora10_45@mail.ru
PhD, Doctor of Biol. Sci., Professor, Chief Research Fellow, Head of the Laboratory of Pathogenomics and Transcriptomics;
Leading Research Fellow, Laboratory of Molecular Genetics of Complicated Inherited Diseases
8 Baltiyskaya ul., Moscow, 125315, Russian Federation
+7 (917) 545 43 93.
РоссияI. V. Pronina
Institute of General Pathology and Pathophysiology
Email: fake@neicon.ru
PhD (in Biol.), Research Fellow, Laboratory of Pathogenomics and Transcriptomics
8 Baltiyskaya ul., Moscow, 125315, Russian Federation
РоссияD. O. Utkin
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Email: fake@neicon.ru
MD, Surgeon, Applicant, Chair of Clinical Biochemistry and Laboratory Diagnostics, Faculty of Postgraduate Education
20–1 Delegatskaya ul., Moscow, 127473, Russian Federation
РоссияE. A. Filippova
Institute of General Pathology and Pathophysiology
Email: fake@neicon.ru
Postgraduate Student, Junior Research Fellow, Laboratory of Pathogenomics and Transcriptomics
8 Baltiyskaya ul., Moscow, 125315, Russian Federation
РоссияA. M. Burdennyy
Institute of General Pathology and Pathophysiology
Email: fake@neicon.ru
PhD (in Biol.), Leading Research Fellow, Laboratory of Pathogenomics and Transcriptomics
8 Baltiyskaya ul., Moscow, 125315, Russian Federation
Россия
V. I. Loginov
Institute of General Pathology and PathophysiologyMedical Genetic Science Center
Email: fake@neicon.ru
PhD (in Biol.), Leading Research Fellow, Laboratory of Pathogenomics and Transcriptomics; Senior Research Fellow, Laboratory of Molecular Genetics of Complicated Inherited Diseases
8 Baltiyskaya ul., Moscow, 125315, Russian Federation
1 Moskvorech'e ul., Moscow, 115522, Russian Federation
РоссияM. V. Fridman
Vavilov Institute of General Genetics
Email: fake@neicon.ru
PhD (in Biol.), Research Fellow, Laboratory of Systems Biology and Computational Genetics
3 Gubkina ul., Moscow, 119333, Russian Federation
РоссияT. P. Kazubskaya
N.N. Blokhin National Medical Research Centre of Oncology
Email: fake@neicon.ru
MD, PhD, Oncogenetic Physician, Senior Research Fellow, Laboratory of Clinical Oncogenetics
24 Kashirskoe shosse, Moscow, 115478, Russian Federation
РоссияN. E. Kushlinskii
N.N. Blokhin National Medical Research Centre of Oncology
Email: fake@neicon.ru
MD, PhD, Professor, Member-Correspondent of Russian Academy of Sciences, Head of Clinical Biochemistry Laboratory
24 Kashirskoe shosse, Moscow, 115478, Russian Federation
РоссияReferences
- Логинов ВИ, Рыков СВ, Фридман МВ, Брага ЭА. Метилирование генов микрорнк и онкогенез (обзор). Биохимия. 2015;80(2): 184–203.
- Kinose Y, Sawada K, Nakamura K, Kimura T. The role of microRNAs in ovarian cancer. Biomed Res Int. 2014;2014:249393. doi: 10.1155/2014/249393.
- Брага ЭА, Фридман МВ, Кушлинский НЕ. Молекулярные механизмы в метастазировании рака яичников: ключевые гены и регуляторные микроРНК. Биохимия. 2017;82(5): 717–31.
- Shi M, Mu Y, Zhang H, Liu M, Wan J, Qin X, Li C. MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: A meta-analysis. Medicine (Baltimore). 2018;97(32):e11505. doi: 10.1097/MD.0000000000011505.
- Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P, Calin GA. Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat Res. 2011;717(1–2): 77–84. doi: 10.1016/j.mrfmmm.2011.03.008.
- Piletič K, Kunej T. MicroRNA epigenetic signatures in human disease. Arch Toxicol. 2016;90(10): 2405–19. doi: 10.1007/s00204-016-1815-7.
- Weisenberger DJ, Liang G, Lenz HJ. DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies. Oncogene. 2018;37(5): 566–77. doi: 10.1038/onc.2017.374.
- Li X, Pan Q, Wan X, Mao Y, Lu W, Xie X, Cheng X. Methylation-associated Has-miR-9 deregulation in paclitaxel-resistant epithelial ovarian carcinoma. BMC Cancer. 2015;15:509. doi: 10.1186/s12885-015-1509-1.
- Брага ЭА, Логинов ВИ, Бурденный АМ, Филиппова ЕА, Пронина ИВ, Куревлев СВ, Казубская ТП, Кушлинский ДН, Уткин ДО, Ермилова ВД, Кушлинский НЕ. Пять гиперметилированных генов микрорнк как потенциальные маркеры рака яичников. Бюллетень экспериментальной биологии и медицины. 2017;164(9): 335–40
- Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO - Classification of Tumours of Female Reproductive Organs. Vol. 6. Lyon: IARC; 2014. 307 p.
- Pronina IV, Loginov VI, Burdennyy AM, Fridman MV, Senchenko VN, Kazubskaya TP, Kushlinskii NE, Dmitriev AA, Braga EA. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression. Gene. 2017;604:1–8. doi: 10.1016/j.gene.2016.12.018.
- Schrijver WA, van Diest PJ; Dutch Distant Breast Cancer Metastases Consortium, Moelans CB. Unravelling site-specific breast cancer metastasis: a microRNA expression profiling study. Oncotarget. 2017;8(2): 3111–23. doi: 10.18632/oncotarget.13623.
- Drasin DJ, Guarnieri AL, Neelakantan D, Kim J, Cabrera JH, Wang CA, Zaberezhnyy V, Gasparini P, Cascione L, Huebner K, Tan AC, Ford HL. TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. Cancer Res. 2015;75(9): 1908–21. doi: 10.1158/0008-5472.CAN-14-2394.
Supplementary files
